Abbott, Pharmacyclics and JNJ's Janssen Biotech subsidiary partnered to evaluate Abbott's fluorescence in situ hybridization (FISH) technology to develop a molecular companion diagnostic to identify chronic lymphocytic leukemia

Pharmacyclics Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$6,218.5m on 03/01/2013 [market cap]

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Abbott Laboratories

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Johnson & Johnson

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced